169.80
5.71 (3.48%)
| Previous Close | 164.09 |
| Open | 163.07 |
| Volume | 1,740,748 |
| Avg. Volume (3M) | 882,229 |
| Market Cap | 4,246,217,984 |
| Price / Sales | 507.09 |
| Price / Book | 13.04 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -2,868.84% |
| Diluted EPS (TTM) | -10.66 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.24% |
| Current Ratio (MRQ) | 8.44 |
| Operating Cash Flow (TTM) | -163.91 M |
| Levered Free Cash Flow (TTM) | -90.04 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -63.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Praxis Precision Medicines, Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -1.00 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 122.02% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 424.00 (BTIG, 149.71%) | Buy |
| Median | 317.00 (86.69%) | |
| Low | 83.00 (Wedbush, -51.12%) | Sell |
| 83.00 (Jones Trading, -51.12%) | Buy | |
| Average | 285.40 (68.08%) | |
| Total | 9 Buy, 1 Sell | |
| Avg. Price @ Call | 190.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 Dec 2025 | 340.00 (100.24%) | Buy | 247.99 |
| 25 Nov 2025 | 258.00 (51.94%) | Buy | 184.25 | |
| Needham | 05 Dec 2025 | 304.00 (79.03%) | Buy | 247.99 |
| 01 Dec 2025 | 250.00 (47.23%) | Buy | 184.56 | |
| Wedbush | 05 Dec 2025 | 83.00 (-51.12%) | Sell | 247.99 |
| 06 Nov 2025 | 77.00 (-54.65%) | Sell | 172.35 | |
| BTIG | 19 Nov 2025 | 424.00 (149.71%) | Buy | 189.32 |
| Chardan Capital | 17 Oct 2025 | 330.00 (94.35%) | Buy | 189.99 |
| Deutsche Bank | 17 Oct 2025 | 280.00 (64.90%) | Buy | 189.99 |
| Guggenheim | 17 Oct 2025 | 350.00 (106.12%) | Buy | 189.99 |
| Truist Securities | 17 Oct 2025 | 360.00 (112.01%) | Buy | 189.99 |
| Jefferies | 16 Oct 2025 | 300.00 (76.68%) | Buy | 162.71 |
| Jones Trading | 18 Sep 2025 | 83.00 (-51.12%) | Buy | 45.23 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |